GLP-1, short for Glucagon-like peptide-1, is a hormone that enhances insulin secretion and suppresses glucagon release, slowing down digestion
More potent than magnesium oxide
The content is not intended to be a substitute for professional advice
When dose reduction is appropriate Phase 3 trials include provisions for dose reduction: Gastrointestinal adverse events or inadequate oral intake may warrant stepping down to a lower dose level see Retatrutide Side Effects for incidence rates by dose BMI reaching 22 kg/m or below , or perceived excessive weight loss, allows dose reduction Treatment is discontinued at BMI 18.5 kg/m or below How Often and When to Take Retatrutide Injection frequency once weekly by subcutaneous injection, on the same day each week
Individuals with inflammatory conditions such as psoriasis who also have metabolic comorbidities might experience dual benefits, though dedicated trials in these populations are lacking
Sourcing Research-Grade Retatrutide What Research-Use-Only Actually Means "Research use only" is a regulatory and labeling designation, not a marketing description
